An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
StatPearls [Internet].
Treasure Island (FL): StatPearls Publishing; 2026 Jan-.
Top results in this bookTable of Contents
GeneReviews® [Internet].
Adam MP, Bick S, Mirzaa GM, et al., editors.
Seattle (WA): University of Washington, Seattle; 1993-2026.
Teriflunomide (Aubagio) (14 mg Film-coated Tablet): Teriflunomide is Indicated as Monotherapy for the Treatment of Patients with Relapsing-Remitting Multiple Sclerosis to Reduce the Frequency of Clinical Exacerbations and to Delay the Accumulation of Physical Disability [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2014 Oct.
Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet].
York (UK): Centre for Reviews and Dissemination (UK); 1995-.
Multiple Sclerosis: Current Status and Strategies for the Future.
Institute of Medicine (US) Committee on Multiple Sclerosis: Current Status and Strategies for the Future; Joy JE, Johnston RB Jr, editors.
Washington (DC): National Academies Press (US); 2001.
Comparative Clinical and Cost-Effectiveness of Drug Therapies for Relapsing-Remitting Multiple Sclerosis [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2013 Oct. (CADTH Therapeutic Review, No. 1.2B.)
LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet].
Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-.
Multiple Sclerosis: Perspectives in Treatment and Pathogenesis [Internet].
Zagon IS, McLaughlin PJ, editors.
Brisbane (AU): Codon Publications; 2017 Nov 27.
Drugs and Lactation Database (LactMed®) [Internet].
Bethesda (MD): National Institute of Child Health and Human Development; 2006-.
Urinary Incontinence in Neurological Disease: Management of Lower Urinary Tract Dysfunction in Neurological Disease.
National Clinical Guideline Centre (UK).
London: Royal College of Physicians (UK); 2012 Aug. (NICE Clinical Guidelines, No. 148.)
Autoimmunity: From Bench to Bedside [Internet].
Anaya JM, Shoenfeld Y, Rojas-Villarraga A, et al., editors.
Bogota (Colombia): El Rosario University Press; 2013 Jul 18.
Clinical Review Report: Ocrelizumab (Ocrevus): (Hoffmann-La Roche Limited): Indication: Treatment of adult patients with relapsing-remitting multiple sclerosis (RRMS) with active disease defined by clinical and imaging features [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 Dec.
Clinical Review Report: Siponimod (Mayzent): (Novartis Pharmaceuticals Canada Inc.): Indication: Secondary-progressive multiple sclerosis [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2020 Sep.
Clinical Review Report: Daclizumab (Zinbryta) [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 Jul.
Clinical Review Report: Ocrelizumab (Ocrevus): (Hoffmann-La Roche Limited): Indication: Management of adult patients with early primary progressive multiple sclerosis as defined by disease duration and level of disability, in conjunction with imaging features characteristic of inflammatory activity [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 May.
Clinical effectiveness and cost-effectiveness of beta-interferon and glatiramer acetate for treating multiple sclerosis: systematic review and economic evaluation.
Melendez-Torres GJ, Auguste P, Armoiry X, et al.
Southampton (UK): NIHR Journals Library; 2017 Sep. (Health Technology Assessment, No. 21.52.)
Clinical Review Report: Cladribine (Mavenclad): (EMD Serono): Indication: As monotherapy for the treatment of adult patients with relapsing-remitting multiple sclerosis (RRMS) to reduce the frequency of clinical exacerbations and delay the progression of disability. Cladribine is generally recommended in RRMS patients who have had an inadequate response to, or are unable to tolerate, one or more therapies for RRMS [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Oct.
Natalizumab and Tyruko (natalizumab biosimilar) for treating highly active relapsing-remitting multiple sclerosis after at least one disease-modifying therapy: a systematic review and economic model.
Manzano CL, Sadek A, Cooper C, et al.
Southampton (UK): National Institute for Health and Care Research; 2026 Aug. (Health Technology Assessment, No. 30.60.)
Endotext [Internet].
Feingold KR, Adler RA, Ahmed SF, et al., editors.
South Dartmouth (MA): MDText.com, Inc.; 2000-.
Madame Curie Bioscience Database [Internet].
Austin (TX): Landes Bioscience; 2000-2013.
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on